
CJC-1295 No DAC
10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.
Free U.S. shipping $175+

IGF-1 LR3 is a recombinant analog of insulin-like growth factor 1 carrying an arginine substitution at position 3 and a 13-residue N-terminal extension.
Those changes sharply reduce its affinity for IGF binding proteins, which is the specific property that makes it valuable in cell-culture research: more of the added peptide remains free to engage the IGF-1 receptor rather than being sequestered by binding proteins present in serum.
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Analytical values reflect per-lot documentation and appear once a batch is released.
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
IGF-1 LR3 was developed as a research analog to overcome the binding-protein sequestration that limits native IGF-1 activity in culture systems.
It has become one of the most cited IGF reagents in cell-culture literature, particularly for extended-signaling experimental designs.

10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.

5/5 mg
Combined GHRH analog and secretagogue receptor agonist preparation for dual-input pituitary research.

5 mg
GHRH analog with Drug Affinity Complex modification for extended-duration receptor research.

10 mg
Second-generation growth hormone releasing peptide studied as a ghrelin receptor agonist reference.